Trial Profile
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin (Primary)
- Indications Advanced breast cancer; Carcinoma; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 02 Jan 2024 Planned End Date changed from 30 Nov 2023 to 15 Nov 2024.
- 16 Aug 2021 Planned primary completion date changed from 1 Nov 2022 to 30 Nov 2022.
- 21 Jul 2021 Planned End Date changed from 1 Nov 2023 to 30 Nov 2023.